- Trial phase
- Approved
- Time to market
- Already approved and commercially launched (August 2025).
- Why 4/10
- PAPZIMEOS is already FDA-approved and commercially launched with no pending PDUFA or pivotal readout. The next hard catalyst would be a potential EMA decision for European approval, but no date is confirmed. As an approved drug with no imminent binary regulatory catalyst, the impact score is capped at 4 per the rubric.
Watch for the pace of PAPZIMEOS revenue growth in upcoming quarterly reports, particularly whether the drug can maintain its 37% sequential growth trajectory against the new competition from Inovio's VOCERYQ, which was approved on October 30, 2026. Also monitor for a potential EMA marketing authorization application decision for European expansion, which could open a new market.
Price Chart
Executive Summary
PAPZIMEOS (zopapogene imadenovec, formerly PRGN-2012) is Precigen's first and only FDA-approved product, a gene therapy immunotherapy for adults with recurrent respiratory papillomatosis (RRP), a rare HPV-caused airway disease. It received full FDA approval in August 2025 and seven-year orphan drug exclusivity through 2032. The drug has launched strongly, generating $72.9M in Q3 2026 revenue (37% sequential growth) and $151M launch-to-date, driving the company to its first positive operating cash flow quarter. However, on October 30, 2026, Inovio's competing product VOCERYQ received accelerated FDA approval for the same indication, sending PGEN stock down 26%. PAPZIMEOS is Precigen's sole marketed product, making the company a single-product commercial-stage biopharma with concentrated risk.
How It Works
PAPZIMEOS is a gene therapy / immunotherapy delivered as an injection. It uses a harmless, non-replicating adenovirus (a common cold virus shell) as a delivery vehicle to carry genetic instructions into the patient's cells. These instructions train the immune system to recognize and attack cells infected with human papillomavirus (HPV) types 6 and 11, which cause benign but recurring tumors in the airway (recurrent respiratory papillomatosis). By stimulating an immune response against the virus, the drug aims to reduce or eliminate the need for repeated surgeries to remove these growths.
Trial Status
PAPZIMEOS received full FDA approval in August 2025 based on a pivotal Phase 1/2 study in which 51% of evaluable patients required no surgical intervention for 12 months. The drug is now commercially available in the US. Long-term durability data presented in May 2026 showed complete responses beyond 4 years. The FDA granted seven-year orphan drug exclusivity in May 2026, effective through August 14, 2032.
The Two-Sided Case
Upcoming Catalysts
- Q4 2026 earnings report (late February/early March 2027) - revenue growth trajectory and market share against Inovio's VOCERYQ
- Potential EMA marketing authorization application decision for European expansion (no confirmed date)
- PAPZIMEOS revenue growth and market penetration metrics in quarterly reports
- Any label expansion or new clinical data presentations at medical conferences
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PRECIGEN, INC. 8-K PGEN ·Originating report